338 related articles for article (PubMed ID: 28377251)
1. Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression.
Grau SJ; Hampl JA; Kohl AC; Timmer M; Duval IV; Blau T; Ruge MI; Goldbrunner RH
World Neurosurg; 2017 Jul; 103():180-185. PubMed ID: 28377251
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Factors in Lobar World Health Organization Grade II Astrocytomas.
Waqar M; Hanif S; Brodbelt AR; Rathi N; Das K; Zakaria R; Walker C; Jenkinson MD
World Neurosurg; 2015 Jul; 84(1):154-62. PubMed ID: 25779854
[TBL] [Abstract][Full Text] [Related]
3. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
Beiko J; Suki D; Hess KR; Fox BD; Cheung V; Cabral M; Shonka N; Gilbert MR; Sawaya R; Prabhu SS; Weinberg J; Lang FF; Aldape KD; Sulman EP; Rao G; McCutcheon IE; Cahill DP
Neuro Oncol; 2014 Jan; 16(1):81-91. PubMed ID: 24305719
[TBL] [Abstract][Full Text] [Related]
4. Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas.
Hong JB; Roh TH; Kang SG; Kim SH; Moon JH; Kim EH; Ahn SS; Choi HJ; Cho J; Suh CO; Chang JH
Cancer Res Treat; 2020 Oct; 52(4):1041-1049. PubMed ID: 32324987
[TBL] [Abstract][Full Text] [Related]
5. Early prognostic factors related to progression and malignant transformation of low-grade gliomas.
Jung TY; Jung S; Moon JH; Kim IY; Moon KS; Jang WY
Clin Neurol Neurosurg; 2011 Nov; 113(9):752-7. PubMed ID: 21889256
[TBL] [Abstract][Full Text] [Related]
6. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
[TBL] [Abstract][Full Text] [Related]
7. Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
McGirt MJ; Chaichana KL; Gathinji M; Attenello FJ; Than K; Olivi A; Weingart JD; Brem H; Quiñones-Hinojosa AR
J Neurosurg; 2009 Jan; 110(1):156-62. PubMed ID: 18847342
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of surgically treated low-grade gliomas: a retrospective analysis of a single institute.
Turkoglu E; Gurer B; Sanli AM; Dolgun H; Gurses L; Oral NA; Donmez T; Sekerci Z
Clin Neurol Neurosurg; 2013 Dec; 115(12):2508-13. PubMed ID: 24225484
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of prognostic factors on survival in patients with low grade glioma.
Durmaz R; Vural M; Işildi E; Coşan E; Ozkara E; Bal C; Ciftçi E; Arslantaş A; Atasoy MA
Turk Neurosurg; 2008 Oct; 18(4):336-44. PubMed ID: 19107679
[TBL] [Abstract][Full Text] [Related]
11. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
[TBL] [Abstract][Full Text] [Related]
12. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Ahmadi R; Stockhammer F; Becker N; Hohlen K; Misch M; Christians A; Dictus C; Herold-Mende C; Capper D; Unterberg A; von Deimling A; Wick W; Hartmann C
J Neurooncol; 2012 Aug; 109(1):15-22. PubMed ID: 22528790
[TBL] [Abstract][Full Text] [Related]
13. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
Nitta M; Muragaki Y; Maruyama T; Ikuta S; Komori T; Maebayashi K; Iseki H; Tamura M; Saito T; Okamoto S; Chernov M; Hayashi M; Okada Y
Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
[TBL] [Abstract][Full Text] [Related]
14. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
15. IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
Iwadate Y; Matsutani T; Hirono S; Ikegami S; Shinozaki N; Saeki N
J Neurooncol; 2015 Sep; 124(3):493-500. PubMed ID: 26243269
[TBL] [Abstract][Full Text] [Related]
16. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
[TBL] [Abstract][Full Text] [Related]
17. Effect of Gross Total Resection in World Health Organization Grade II Astrocytomas: SEER-Based Survival Analysis.
Schupper AJ; Hirshman BR; Carroll KT; Ali MA; Carter BS; Chen CC
World Neurosurg; 2017 Jul; 103():741-747. PubMed ID: 28419878
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
Yao Y; Chan AK; Qin ZY; Chen LC; Zhang X; Pang JC; Li HM; Wang Y; Mao Y; Ng HK; Zhou LF
PLoS One; 2013; 8(6):e67421. PubMed ID: 23840696
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
[TBL] [Abstract][Full Text] [Related]
20. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas.
McGirt MJ; Chaichana KL; Attenello FJ; Weingart JD; Than K; Burger PC; Olivi A; Brem H; Quinoñes-Hinojosa A
Neurosurgery; 2008 Oct; 63(4):700-7; author reply 707-8. PubMed ID: 18981880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
